Modifying release characteristics from 3D printed drug-eluting products

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Modifying release characteristics from 3D printed drug-eluting products. / Boetker, Johan; Water, Jorrit; Aho, Johanna; Arnfast, Lærke; Bohr, Adam; Rantanen, Jukka.

In: European Journal of Pharmaceutical Sciences, Vol. 90, 2016, p. 47-52.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Boetker, J, Water, J, Aho, J, Arnfast, L, Bohr, A & Rantanen, J 2016, 'Modifying release characteristics from 3D printed drug-eluting products', European Journal of Pharmaceutical Sciences, vol. 90, pp. 47-52. https://doi.org/10.1016/j.ejps.2016.03.013

APA

Boetker, J., Water, J., Aho, J., Arnfast, L., Bohr, A., & Rantanen, J. (2016). Modifying release characteristics from 3D printed drug-eluting products. European Journal of Pharmaceutical Sciences, 90, 47-52. https://doi.org/10.1016/j.ejps.2016.03.013

Vancouver

Boetker J, Water J, Aho J, Arnfast L, Bohr A, Rantanen J. Modifying release characteristics from 3D printed drug-eluting products. European Journal of Pharmaceutical Sciences. 2016;90:47-52. https://doi.org/10.1016/j.ejps.2016.03.013

Author

Boetker, Johan ; Water, Jorrit ; Aho, Johanna ; Arnfast, Lærke ; Bohr, Adam ; Rantanen, Jukka. / Modifying release characteristics from 3D printed drug-eluting products. In: European Journal of Pharmaceutical Sciences. 2016 ; Vol. 90. pp. 47-52.

Bibtex

@article{77b590c1aaee40869c0c8bc6dc3636a7,
title = "Modifying release characteristics from 3D printed drug-eluting products",
abstract = "Abstract This work describes an approach to modify the release of active compound from a 3D printed model drug product geometry intended for flexible dosing and precision medication. The production of novel polylactic acid and hydroxypropyl methylcellulose based feed materials containing nitrofurantoin for 3D printing purposes is demonstrated. Nitrofurantoin, Metolose{\textregistered} and polylactic acid were successfully co-extruded with up to 40% Metolose{\textregistered} content, and subsequently 3D printed into model disk geometries ({\o}10 mm, h = 2 mm). Thermal analysis with differential scanning calorimetry and solid phase identification with Raman spectroscopy showed that nitrofurantoin remained in its original solid form during both hot-melt extrusion and subsequent 3D printing. Rheological measurements of the different compositions showed that the flow properties were sensitive to the amount of undissolved particles present in the formulation. Release of nitrofurantoin from the disks was dependent on Metolose{\textregistered} loading, with higher accumulated release observed for higher Metolose{\textregistered} loads. This work shows the potential of custom-made, drug loaded feed materials for 3D printing of precision drug products with tailored drug release characteristics.",
keywords = "Controlled release/delivery, Polylactic acid (PLA), Biodegradable polymers, Rheology, Extrusion, 3D printing Biofilm, Antimicrobial Implant",
author = "Johan Boetker and Jorrit Water and Johanna Aho and L{\ae}rke Arnfast and Adam Bohr and Jukka Rantanen",
year = "2016",
doi = "10.1016/j.ejps.2016.03.013",
language = "Dansk",
volume = "90",
pages = "47--52",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Modifying release characteristics from 3D printed drug-eluting products

AU - Boetker, Johan

AU - Water, Jorrit

AU - Aho, Johanna

AU - Arnfast, Lærke

AU - Bohr, Adam

AU - Rantanen, Jukka

PY - 2016

Y1 - 2016

N2 - Abstract This work describes an approach to modify the release of active compound from a 3D printed model drug product geometry intended for flexible dosing and precision medication. The production of novel polylactic acid and hydroxypropyl methylcellulose based feed materials containing nitrofurantoin for 3D printing purposes is demonstrated. Nitrofurantoin, Metolose® and polylactic acid were successfully co-extruded with up to 40% Metolose® content, and subsequently 3D printed into model disk geometries (ø10 mm, h = 2 mm). Thermal analysis with differential scanning calorimetry and solid phase identification with Raman spectroscopy showed that nitrofurantoin remained in its original solid form during both hot-melt extrusion and subsequent 3D printing. Rheological measurements of the different compositions showed that the flow properties were sensitive to the amount of undissolved particles present in the formulation. Release of nitrofurantoin from the disks was dependent on Metolose® loading, with higher accumulated release observed for higher Metolose® loads. This work shows the potential of custom-made, drug loaded feed materials for 3D printing of precision drug products with tailored drug release characteristics.

AB - Abstract This work describes an approach to modify the release of active compound from a 3D printed model drug product geometry intended for flexible dosing and precision medication. The production of novel polylactic acid and hydroxypropyl methylcellulose based feed materials containing nitrofurantoin for 3D printing purposes is demonstrated. Nitrofurantoin, Metolose® and polylactic acid were successfully co-extruded with up to 40% Metolose® content, and subsequently 3D printed into model disk geometries (ø10 mm, h = 2 mm). Thermal analysis with differential scanning calorimetry and solid phase identification with Raman spectroscopy showed that nitrofurantoin remained in its original solid form during both hot-melt extrusion and subsequent 3D printing. Rheological measurements of the different compositions showed that the flow properties were sensitive to the amount of undissolved particles present in the formulation. Release of nitrofurantoin from the disks was dependent on Metolose® loading, with higher accumulated release observed for higher Metolose® loads. This work shows the potential of custom-made, drug loaded feed materials for 3D printing of precision drug products with tailored drug release characteristics.

KW - Controlled release/delivery

KW - Polylactic acid (PLA)

KW - Biodegradable polymers

KW - Rheology

KW - Extrusion

KW - 3D printing Biofilm

KW - Antimicrobial Implant

U2 - 10.1016/j.ejps.2016.03.013

DO - 10.1016/j.ejps.2016.03.013

M3 - Tidsskriftartikel

C2 - 26987609

VL - 90

SP - 47

EP - 52

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

ER -

ID: 160046647